Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients.

about

Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients.

Item

http://www.wikidata.org/entity/Q39303306

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Prognostic and predictive mark ...... all-cell lung cancer patients.

@en

Prognostic and predictive mark ...... all-cell lung cancer patients.

@nl

type

Item

label

Prognostic and predictive mark ...... all-cell lung cancer patients.

@en

Prognostic and predictive mark ...... all-cell lung cancer patients.

@nl

prefLabel

Prognostic and predictive mark ...... all-cell lung cancer patients.

@en

Prognostic and predictive mark ...... all-cell lung cancer patients.

@nl

P1476

Prognostic and predictive mark ...... all-cell lung cancer patients.

@en

P2093

Gerold Bepler

http://www.w3.org/2001/XMLSchema#string

Shirish M Gadgeel

http://www.w3.org/2001/XMLSchema#string

P2860

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.

The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Non-small cell lung cancer.

P304

1909-1921

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.160

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24295420

http://www.w3.org/2001/XMLSchema#string